Eli Lilly and Co
Cramer's 7 days in advance: Earnings year kicks off following JPMorgan Health care Convention
CNBC’s Jim Cramer on Friday instructed traders what to observe for on Wall Street next 7 days, highlighting JPMorgan‘s industry-shifting health-care meeting in San Francisco. Getting location from Monday to Thursday, the meeting is a single of the year’s most significant gatherings of key industry CEOs where they expose earnings assistance and updates on clinical […]
Read More
Eli Lilly's direct drug sales alone may not upend the industry, but others could follow suit
Sopa Images | Lightrocket | Getty Images Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, including its red-hot weight loss treatment Zepbound, to expand patient access. The company’s direct-to-consumer push announced Thursday, the first of its kind for a big drugmaker, […]
Read More
Eli Lilly launches website to help patients get weight loss drugs
Drugmaker Eli Lilly announced on Thursday a new website that will allow patients to get a weight loss drug prescription through a telehealth provider — a move, the company says, that will improve access to the extremely popular and effective drugs, including its recently approved drug, Zepbound. The new website, called LillyDirect, joins a growing list of platforms like Weight […]
Read More
Shares earning the most important moves midday: Xerox, SoFi, Charles Schwab and much more
Test out the firms making headlines in midday investing. Xerox — Xerox shares sank extra than 9% soon after the electronic printing enterprise introduced plans to reduce 15% of its workforce in the initial quarter as portion of a broader restructuring energy. SoFi Technologies — The fiscal know-how inventory tumbled more than 13% next a […]
Read More
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because […]
Read More
Obesity and Alzheimer's drugs pack one-two punch to power Eli Lilly higher in 2024
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer […]
Read More
Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed shares of Novo Nordisk, the maker […]
Read More
Here are the big health sector themes to watch next year
An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and […]
Read More
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The weight loss drug market transformed into the pharmaceutical industry’s newest gold rush this year, as demand for costly but highly effective treatments from Novo Nordisk […]
Read More
Here’s a rapid-fire update on all 33 stocks in our portfolio, including those Cramer would buy on dips
Jim Cramer ran through all 33 stocks in his Charitable Trust portfolio during the December edition of the CNBC Investing Club’s Monthly Meeting. Source
Read More